There's a joke on Wall Street that analysts never saw an S&P 500 stock they didn't like. Well, that doesn't seem to be the case now. Analysts think six stocks in the S&P 500, including Moderna (MRNA), Skyworks Solutions (SWKS) and Illumina (ILMN) are 7% or more overvalued vs. their 12-month price targets, says an Investor's Business Daily analysis of…
Extract — continue reading at the source.
Related stories
Trump’s diesel ban would hurt America and help China
US Treasury yields soar after strong data fuels bets on further rate rises
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
ARM Vs. AMD: Who Is Going to Win the Agentic AI CPU Revival War?
Prediction: This Out-of-Favor Dividend Stock Could Have Significant Upside
She Cashed Out Her Father’s $220,000 IRA the Year She Inherited It, on Top of Her $90,000 Salary. Spreading It Across the Full Window Would Have Kept Nearly All of It Out of the Top Brackets She Paid